Abstract: A display method includes: creating a global container and a virtual display; determining a display-hidden state of a target pixel; performing image splitting processing on a sub-image whose display-hidden state is a display state in the image to be displayed based on a naked-eye 3D film parameter of the virtual display, to obtain left-right eye views; in a case that the display-hidden state of the target pixel is the display state, determining a current refresh position of the target pixel; performing image interleaving processing on the left-right eye views to obtain a first vector texture; updating the first vector texture according to the current refresh position to obtain a second vector texture after rotation; and pushing the second vector texture to the global container, and outputting the second vector texture to the virtual display based on the global container, to obtain a target stereoscopic image.

Abstract: A method for information display, includes: creating a global container and a virtual display corresponding to the terminal device; performing, based on a naked-eye 3D film parameter of the virtual display, image splitting processing on a resource to be displayed to obtain left-right eye views with a naked-eye 3D effect; performing image interleaving processing on the left-right eye views to obtain a current vector texture corresponding to the resource to be displayed; and pushing the current vector texture to the global container, and outputting the current vector texture to the virtual display based on the global container, to render the current vector texture by using the virtual display.

Abstract: Provided is a peptide compound comprising the amino acid sequence: Xaa1-Lys-Xaa3-Ser-Xaa5-Xaa6-Xaa7-Xaa8-Xaa9-Xaa10-Xaa11-Xaa12-Xaa13 wherein: Xaa1 represents Ala or Ser, or is absent, wherein the N-terminal amino acid optionally includes an N-terminal 3,4-dihydrocinnamic acid group; Xaa5 represents Tyr, DOPA or a single bond; Xaa3 and Xaa6 independently represent Pro, Hyp or diHyp; Xaa7, Xaa8, Xaa9, Xaa10, and Xaa11 are each optional (in which case Xaa6 is bonded to Xaa12), and are independently selected from the group Pro, Hyp, diHyp, Thr, DOPA and Tyr; Xaa12 represents Pro, Hyp, diHyp, Thr, DOPA or Tyr; and Xaa13 represents Lys or is absent, as well as regioisomers, stereoisomers, and pharmaceutically- or cosmetically-acceptable salts of said peptide compound, provided that when the N-terminal 3,4-dihydrocinnamic acid group is not present, Xaa1 represents Ala or is absent and Xaa13 represents Lys, then Xaa12 represents Pro, Hyp, diHyp or Thr.

Abstract: A semiconductor memory comprising: a comparison readout circuit comprising a first port configured to receive an electric signal of a read memory unit and a second port configured to receive a reference electric signal, the comparison readout circuit being configured to compare the electric signal of the read memory unit with the reference electric signal to obtain storage information of the memory unit; and a first/second column decoder connected to a first/second memory array and the comparison readout circuit and configured to select a bitline corresponding to the read memory unit when a memory array selection signal enables the first/second memory array, and output the electric signal of the memory unit to the first port by means of the bitline, and further configured to connect a first bitline of the first/second memory array to the second port when the memory array selection signal does not enable the first/second memory array.

Abstract: There is provided topical pharmaceutical formulations comprising montelukast, or a pharmaceutically acceptable salt of solvate thereof, as well as combination products comprising (a) at least one mussel adhesive protein or a derivative thereof; and (b) montelukast, or a pharmaceutically-acceptable salt or solvate thereof. The formulations and combination products find particular utility in direct topical administration for the treatment of inflammation, of inflammatory disorders and/or of condition characterized by inflammation, including wounds, burns, psoriasis, acne and atopic dermatitis.

Abstract: An unreal engine graphic construction method includes the following steps: receiving data to be displayed; determining a number N of basic graphics contained in a graphic to be constructed according to the data to be displayed, wherein, N>1; calling an underlying function at a blueprint layer to draw N of the basic graphics in sequence, wherein the underlying function is used for creating the basic graphics.

Abstract: An unreal engine graphic construction method includes the following steps: receiving data to be displayed; determining a number N of basic graphics contained in a graphic to be constructed according to the data to be displayed, wherein, N>1; calling an underlying function at a blueprint layer to draw N of the basic graphics in sequence, wherein the underlying function is used for creating the basic graphics.

Abstract: Provided is a modified peptide compound comprising one or more of the peptide components (a), (b) or (c): (a) a peptide component of formula I, A-Q-B I A and B represent Z or represent A1-1-B1, A1 and B1 independently represent Z or A2-Q2-B2, A2 and B2 independently represent Z or Z-Q3-Z, Q1, Q2 and Q3 represent, for example, Lys and Z represents a peptide component of the amino acid sequence: [W-Lys-X1-Ser-U-X2-Y] n-W-Lys-X1-Ser-U-X2-Y- (SEQ ID No: 3) (b) a peptide component of the amino acid sequence: [Ala-Lys-X1-Ser-U-X2-Y] p-Ala-Lys-X1-Ser-U-X2-Y-G (SEQ ID No: 4); or (c) a peptide component of the amino acid sequence: W1-Lys-X1-Ser-U1-X2-Y-G (SEQ ID No: 5) wherein: n p, W, W1, X1, U, U1, X2, Y and G have meanings given in the description, and wherein the peptide component is modified to include a labelling groups or labelling components that is/are capable of medical imaging of internal regions of the body non-invasively, and/or of diagnosing and/or therapeutically treating one or more diseases (such as c

Abstract: There is provided a peptide of the sequence Ala-Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-Tyr-Lys, or a salt thereof, for use as a pharmaceutical. The peptide is particularly useful in the treatment of conditions characterised by inflammation, including wounds, burns, hemorrhoids, psoriasis, acne, 5 atopic dermatitis, COPD ulcerative colitis and IPF.

Abstract: A semiconductor memory, comprising a negative voltage providing unit, which is used for providing a first negative voltage to a word line during a read operation, and comprises: a clamping unit that comprises an input end, a control end and an output end, wherein the input end is coupled to a common ground end of the memory, and the control end is used for receiving a first signal; an energy storage capacitor, a first end of which is coupled to the output end, and a second end that is used for receiving a second signal; and a negative voltage providing end which is coupled to the first end, wherein the clamping unit is used for: pulling the voltage at the output end to the voltage at the input end when the first signal is “0”; and clamping the output end at a clamping voltage when the first signal is “1”.

Abstract: Provided a peptide of the sequence Ala-Lys-Pro-Ser-Tyr-Hyp-Hyp-Thr-DOPA-Lys or a salt thereof for use in the treatment of inflammation, of an inflammatory disorder and/or of ion thea condition characterized by inflammation, including wounds, burns, psoriasis, acne and atopic dermatitis.

Abstract: The present invention relates to a preparation method for a semiconductor material leg array and a batch preparation method for an interface layer of a semiconductor material leg array. The preparation method for a semiconductor material leg array comprises: placing a semiconductor block material on a surface of an extrusion mold, placing the semiconductor block material and the extrusion mold in a pressure-resistant sleeve, subjecting the semiconductor block material to plastic deformation by extrusion and filling holes that are arranged in an array on the surface of the extrusion mold, and demolding to obtain a semiconductor material leg array.

Abstract: A compound comprising the amino acid sequence: W-Lys-X1-Ser-U-X2-Y-G wherein W, X1, U, X2 and Y and G have meanings given in the description, as well as regioisomers, stereoisomers, and pharmaceutically- or cosmetically-acceptable salts of said peptide compounds. The compounds arc particularly useful in the treatment of conditions characterized by inflammation. including wounds. burns, and disorders of the mucosa. such as anorectal diseases, inflammatory bowel diseases. gynaecological diseases and dental diseases.

Abstract: Provided is a modified peptide compound comprising one or more of the peptide components (a), (b) or (c): (a) a peptide component of formula I, A-Q-B I A and B represent Z or represent A1-1-B1, A1 and B1 independently represent Z or A2-Q2-B2, A2 and B2 independently represent Z or Z-Q3-Z, Q1, Q2 and Q3 represent, for example, Lys and Z represents a peptide component of the amino acid sequence: [W-Lys-X1-Ser-U-X2-Y] n-W-Lys-X1-Ser-U-X2-Y- (SEQ ID No: 3) (b) a peptide component of the amino acid sequence: [Ala-Lys-X1-Ser-U-X2-Y] p-Ala-Lys-X1-Ser-U-X2-Y-G (SEQ ID No: 4); or (c) a peptide component of the amino acid sequence: W1-Lys-X1-Ser-U1-X2-Y-G (SEQ ID No: 5) wherein: n p, W, W1, X1, U, U1, X2, Y and G have meanings given in the description, and wherein the peptide component is modified to include a labelling groups or labelling components that is/are capable of medical imaging of internal regions of the body non-invasively, and/or of diagnosing and/or therapeutically treating one or more diseases (such as c

Abstract: Provided are a conjugate formed between an anaesthetic compound and a peptide component of the amino acid sequence: W-Lys-X1-Ser-U-X2-Y, wherein: W, X1, U, X2 and Y are as defined in the description, as well as regioisomers, stereoisomers, and pharmaceutically- or cosmetically-acceptable salts of said conjugates, which conjugates are useful in the treatment of conditions characterised by inflammation and/or of pain. Preferred anaesthetics are local anaesthetics, such as procaine.

Abstract: Provided is a peptide compound comprising the amino acid sequence: G-W-Lys-X1-Ser-U-X2-Y-Z-Q wherein: G represents an optional N-terminal a 3,4-dihydrocinnamic acid group; W represents Ala or Ser, or is absent; U represents Tyr, DOPA or a single bond; X1 and X2 independently represent Pro, Hyp or diHyp; Y represents a single bond or represents a 1 to 5 amino acid sequence, in which the amino acids are selected from one or more of the group Pro, Hyp, diHyp, Thr, DOPA and Tyr; Z represents Pro, Hyp, diHyp, Thr, DOPA or Tyr; and Q represents Lys or is absent, as well as regioisomers, stereoisomers, and pharmaceutically- or cosmetically-acceptable salts of said peptide compound, provided that when G is not present, W represents Ala or is absent and Q represents Lys, then Z represents Pro, Hyp, diHyp or Thr.

Abstract: There is provided topical pharmaceutical formulations comprising montelukast, or a pharmaceutical acceptable salt of solvate thereof, as well as combination products comprising (a) at least one mussel adhesive protein or a derivative thereof; and (b) montelukast, or a pharmaceutically-acceptable salt or solvate thereof. The formulations and combination products find particular utility in direct topical administration for the treatment of inflammation, of inflammatory disorders and/or of condition characterized by inflammation, including wounds, burns, psoriasis, acne and atopic dermatitis.

Abstract: A display device include a first light emitting diode (LED), a second LED, and at least one processor of a driver. The processor drives the first LED and the second LED. The processor determines a first pulse width associated with the first LED and a second pulse width associated with the second LED based on a level of brightness to be emitted by the first LED and the second LED. The processor also receives a gap clock and determines a first pulse start time and a first pulse end time for the first LED based on the first pulse width. Moreover, the processor determines a second pulse start time and a second pulse end time for the second LED based on the first pulse end time, the second pulse width, and/or the gap clock, in which the first pulse end time and the second pulse end time are different.

Abstract: There is provided a peptide-containing compound that comprises a peptide component which is an amino acid sequence of from 2 to 45 (e.g. from 6 to 15) amino acids, which peptide component is covalently bonded to one or more compounds of the formula I: wherein: R1 is selected from the group consisting of —C(CH3)2OH, —COCH3, —C(CH3)?CH2 and —C(CH3)2H; and n is 0, 1 or 2, as well as regioisomers, stereoisomers, and pharmaceutically- or cosmetically-acceptable salts of said peptide-containing compound. The compound of formula I is preferably montelukast, montelukast styrene or hydrogenated montelukast styrene. The peptide-containing compound is particularly useful in the treatment of conditions characterised by inflammation, including wounds, hemorrhoids, burns, psoriasis, acne, atopic dermatitis, allergic rhinitis, allergic conjunctivitis, chronic obstructive pulmonary disease, inflammatory bowel disease (such as ulcerative colitis).

Abstract: Light emitting diode display panels with an open loop amplifier resulting in better brightness accuracy and matching between multiple light emitting diode strings.